RU2019121646A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019121646A3 RU2019121646A3 RU2019121646A RU2019121646A RU2019121646A3 RU 2019121646 A3 RU2019121646 A3 RU 2019121646A3 RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A3 RU2019121646 A3 RU 2019121646A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434185P | 2016-12-14 | 2016-12-14 | |
| US62/434,185 | 2016-12-14 | ||
| PCT/US2017/066519 WO2018112258A1 (en) | 2016-12-14 | 2017-12-14 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019121646A RU2019121646A (ru) | 2021-01-15 |
| RU2019121646A3 true RU2019121646A3 (ru) | 2021-03-17 |
Family
ID=60888760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121646A RU2019121646A (ru) | 2016-12-14 | 2017-12-14 | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10912778B2 (ru) |
| EP (2) | EP3554507A1 (ru) |
| JP (3) | JP2020502121A (ru) |
| CN (1) | CN110381951A (ru) |
| AU (3) | AU2017378409A1 (ru) |
| BR (1) | BR112019012251A2 (ru) |
| CA (1) | CA3046025A1 (ru) |
| MX (1) | MX2019006938A (ru) |
| RU (1) | RU2019121646A (ru) |
| WO (1) | WO2018112258A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700989T3 (es) | 2012-12-21 | 2019-02-20 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
| IL262720B2 (en) | 2016-05-05 | 2024-06-01 | Liquidia Tech Inc | Dry powder treprostinil for the treatment of pulmonary hypertension |
| CN110381951A (zh) | 2016-12-14 | 2019-10-25 | 瑞必治公司 | 用于治疗肺性高血压和其他肺病症的方法及组合物 |
| WO2018132371A2 (en) * | 2017-01-10 | 2018-07-19 | United Therapeutics Corporation | Methods and compositions for treating pulmonary hypertension |
| SG11202110533RA (en) * | 2019-04-10 | 2021-10-28 | Mayo Found Medical Education & Res | Methods and materials for gender-dependent treatment of cardiovascular dysfunction |
| CA3142758A1 (en) * | 2019-06-10 | 2020-12-17 | Respira Therapeutics,Inc. | Carrier-based formulations and related methods |
| CN112569210B (zh) * | 2019-09-27 | 2023-09-15 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用马昔腾坦溶液及其制备方法 |
| CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
| CN110946826B (zh) * | 2019-12-12 | 2022-02-22 | 烟台大学 | 一种利奥西呱口服制剂及其制备方法 |
| CN115485000A (zh) | 2020-03-31 | 2022-12-16 | 索芙特海尔公司 | 至少两种液体组合物的气溶胶递送 |
| US11013688B1 (en) * | 2020-05-28 | 2021-05-25 | Softhale Nv | Methods of treatment of viral diseases |
| AU2021369679A1 (en) * | 2020-10-28 | 2023-05-18 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| US20250000873A1 (en) | 2021-09-10 | 2025-01-02 | Justus-Liebig-Universitaet Giessen | Inhaled iloprost for rescue treatment and treatment as needed in pulmonary hypertension |
| WO2024249775A2 (en) * | 2023-05-31 | 2024-12-05 | Respira Therapeutics, Inc. | Methods for treatment of pulmonary hypertension |
| CN116687888A (zh) * | 2023-06-02 | 2023-09-05 | 苏州易合医药有限公司 | 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1493685A (en) | 1970-12-15 | 1977-11-30 | May & Baker Ltd | 8-azapurinones |
| GB1338235A (en) | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| US4883812A (en) | 1976-08-17 | 1989-11-28 | Burroughs Wellcome Co. | Treatment of hypertension using prostacyclin |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| DE3417638A1 (de) | 1984-05-10 | 1985-11-14 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| DK1174431T3 (da) | 1997-11-12 | 2012-08-20 | Bayer Pharma AG | 2-phenyl-substitueret imidazo triazinon som phoshodiesterase-inhibitorer |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| WO2001008686A1 (en) | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
| CA2383466C (en) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
| KR100610131B1 (ko) | 2000-09-06 | 2006-08-09 | 다나베 세이야꾸 가부시키가이샤 | 경구 투여용 제제 |
| KR100564466B1 (ko) | 2001-03-28 | 2006-03-29 | 화이자 인코포레이티드 | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 |
| TWI316055B (ru) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20040077624A1 (en) | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
| EP1658060A2 (en) | 2003-08-22 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals Inc. | Methods of treating copd and pulmonary hypertension |
| MX2008000087A (es) | 2005-06-23 | 2008-03-18 | Schering Corp | Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5. |
| KR101351668B1 (ko) | 2006-02-03 | 2014-01-14 | 악텔리온 원 에스에이 | 신규 에포프로스테놀 제형 및 이의 제조방법 |
| KR101390579B1 (ko) * | 2006-05-15 | 2014-05-19 | 유나이티드 세러퓨틱스 코오포레이션 | 정량 흡입기를 사용한 트레프로스티닐 투여 |
| CN101903324B (zh) | 2007-12-17 | 2013-07-03 | 联合治疗公司 | 一种制备Remodulin中的活性成分曲前列素的改良方法 |
| EP2237788A4 (en) | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF |
| EP2280696B9 (en) | 2008-03-18 | 2015-12-09 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| WO2009115235A1 (en) | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
| ES2652590T3 (es) | 2008-08-13 | 2018-02-05 | Actelion Pharmaceuticals Ltd. | Composiciones terapéuticas que contienen macitentan |
| LT2447254T (lt) | 2009-06-26 | 2018-01-10 | Nippon Shinyaku Co., Ltd. | Kristalai |
| WO2011030351A2 (en) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
| US20120225937A1 (en) | 2009-09-23 | 2012-09-06 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pg12 receptor agonists |
| KR20160132501A (ko) * | 2010-03-15 | 2016-11-18 | 유나이티드 세러퓨틱스 코오포레이션 | 폐고혈압의 치료 |
| BR112012028153A2 (pt) | 2010-05-03 | 2018-08-07 | Tsh Biopharm Corporation Ltd | composição farmacêutica e método para o tratamento de hipertensão |
| SG186989A1 (en) | 2010-07-14 | 2013-02-28 | Novartis Ag | Ip receptor agonist heterocyclic compounds |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| JP6050758B2 (ja) | 2010-12-07 | 2016-12-21 | レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 乾燥粉末吸入器及びその作動方法 |
| US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
| ES2974809T3 (es) | 2012-10-31 | 2024-07-01 | Vectura Gmbh | Administración de iloprost en aerosol |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN106794325B (zh) | 2014-02-21 | 2020-06-30 | 瑞必治公司 | 粉末吸入器、系统和方法 |
| BR112017014914B1 (pt) * | 2015-01-13 | 2023-11-14 | Vivus, Inc | Uso de uma combinação de tacrolimus e um segundo agente ativo eficaz no tratamento ou prevenção da hipertensão pulmonar |
| CN110381951A (zh) | 2016-12-14 | 2019-10-25 | 瑞必治公司 | 用于治疗肺性高血压和其他肺病症的方法及组合物 |
-
2017
- 2017-12-14 CN CN201780086527.2A patent/CN110381951A/zh active Pending
- 2017-12-14 JP JP2019531750A patent/JP2020502121A/ja active Pending
- 2017-12-14 RU RU2019121646A patent/RU2019121646A/ru unknown
- 2017-12-14 AU AU2017378409A patent/AU2017378409A1/en not_active Abandoned
- 2017-12-14 EP EP17823002.5A patent/EP3554507A1/en not_active Ceased
- 2017-12-14 CA CA3046025A patent/CA3046025A1/en active Pending
- 2017-12-14 EP EP25178206.6A patent/EP4620525A3/en active Pending
- 2017-12-14 WO PCT/US2017/066519 patent/WO2018112258A1/en not_active Ceased
- 2017-12-14 US US16/469,524 patent/US10912778B2/en active Active
- 2017-12-14 MX MX2019006938A patent/MX2019006938A/es unknown
- 2017-12-14 BR BR112019012251-6A patent/BR112019012251A2/pt unknown
-
2021
- 2021-01-11 US US17/146,173 patent/US11491160B2/en active Active
- 2021-11-23 US US17/534,282 patent/US11491161B2/en active Active
-
2022
- 2022-06-29 US US17/853,005 patent/US12263174B2/en active Active
- 2022-10-17 AU AU2022256085A patent/AU2022256085A1/en not_active Abandoned
- 2022-12-09 JP JP2022197348A patent/JP2023036678A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019782A patent/JP2025065408A/ja active Pending
- 2025-02-26 US US19/064,180 patent/US20250195531A1/en active Pending
- 2025-11-03 AU AU2025260006A patent/AU2025260006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019121646A (ru) | 2021-01-15 |
| EP4620525A2 (en) | 2025-09-24 |
| EP3554507A1 (en) | 2019-10-23 |
| AU2017378409A1 (en) | 2019-07-04 |
| US11491161B2 (en) | 2022-11-08 |
| US11491160B2 (en) | 2022-11-08 |
| US20210205318A1 (en) | 2021-07-08 |
| MX2019006938A (es) | 2019-09-06 |
| JP2020502121A (ja) | 2020-01-23 |
| JP2025065408A (ja) | 2025-04-17 |
| AU2022256085A1 (en) | 2022-11-17 |
| JP2023036678A (ja) | 2023-03-14 |
| US20200093830A1 (en) | 2020-03-26 |
| CA3046025A1 (en) | 2018-06-21 |
| AU2025260006A1 (en) | 2025-11-20 |
| WO2018112258A1 (en) | 2018-06-21 |
| CN110381951A (zh) | 2019-10-25 |
| EP4620525A3 (en) | 2025-12-03 |
| US12263174B2 (en) | 2025-04-01 |
| US20220079949A1 (en) | 2022-03-17 |
| BR112019012251A2 (pt) | 2019-11-05 |
| US10912778B2 (en) | 2021-02-09 |
| US20250195531A1 (en) | 2025-06-19 |
| US20220347183A1 (en) | 2022-11-03 |